Postmenopausal Estrogen/Progestin Interventions (PEPI)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00000466 |
Recruitment Status :
Completed
First Posted : October 28, 1999
Last Update Posted : May 13, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bone Diseases Cardiovascular Diseases Coronary Disease Diabetes Mellitus Heart Diseases Hypercholesterolemia Hypertension Myocardial Ischemia Osteoporosis Thrombosis Postmenopause | Drug: estrogens, conjugated Drug: medroxyprogesterone Drug: progesterone Drug: estrogen replacement therapy | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Masking: | Double |
Primary Purpose: | Prevention |
Study Start Date : | September 1987 |
Actual Study Completion Date : | October 2000 |
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 64 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000466
OverallOfficial: | Mark Espeland | Bowman Gray School of Medicine |
ClinicalTrials.gov Identifier: | NCT00000466 |
Other Study ID Numbers: |
55 U01HL040232 ( U.S. NIH Grant/Contract ) |
First Posted: | October 28, 1999 Key Record Dates |
Last Update Posted: | May 13, 2016 |
Last Verified: | July 2005 |
Osteoporosis Bone Diseases Cardiovascular Diseases Heart Diseases Thrombosis Coronary Disease Myocardial Ischemia Hypercholesterolemia Vascular Diseases Bone Diseases, Metabolic Musculoskeletal Diseases Metabolic Diseases Embolism and Thrombosis Hyperlipidemias Dyslipidemias |
Lipid Metabolism Disorders Medroxyprogesterone Acetate Medroxyprogesterone Progesterone Estrogens, Conjugated (USP) Estrogens Progestins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Contraceptives, Oral, Hormonal Contraceptives, Oral Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents |